Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080457 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Encysive Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00080457 is a Phase 3 study that has completed, run by Encysive Pharmaceuticals. The registered enrollment target is 240 participants.
The verdict
NCT00080457, a Phase 3 study, has completed, sponsored by Encysive Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
Interventions
- DRUG sitaxsentan sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00080457
The ClinicalTrials.gov registry entry for NCT00080457 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Encysive Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sitaxsentan sodium is the first listed.
NCT00080457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00080457 about?
NCT00080457 is a clinical study titled "Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension". The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
What is the current status of trial NCT00080457?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2003-05. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00080457?
The interventions under investigation include: sitaxsentan sodium (DRUG).
Who is sponsoring clinical trial NCT00080457?
This trial is sponsored by Encysive Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.